M1 Kliniken AG

  • WKN: A0STSQ
  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 10.06.2020 | 16:30

M1 Kliniken AG: M1 Kliniken AG acquires 48 % of HAEMATO AG - concentration of both companies on their respective core competencies

DGAP-News: M1 Kliniken AG / Key word(s): Investment/Transaction in Own Shares
10.06.2020 / 16:30
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG: Acquires 48 % of HAEMATO AG - concentration of both companies on their respective core competencies

- M1 Kliniken AG acquires about 48% of the share capital of HAEMATO AG from MPH Health Care AG. Transfer of the HAEMATO shares within the framework of a capital increase through contribution in kind

- Focus of both companies on their respective core competencies beauty and products/trades

Berlin, 10.06.2020 - The management boards of M1 Kliniken AG and MPH Health Care AG today signed an agreement for the acquisition of all HAEMATO AG shares owned by MPH Health Care AG by M1 Kliniken AG. MPH Health Care AG is contributing the shares of HAEMATO AG to M1 Kliniken AG within the framework of a capital increase through contribution in kind. M1 Kliniken AG has already resolved on the relevant resolutions for the implementation of the capital increase through contribution in kind by a total of 2,143,403 new M1 shares. The takeover will be effective as of July 1, 2020.

Once the transaction is implemented, M1 Kliniken AG and HAEMATO AG will be able to strengthen their respective core competencies. In the future, the M1 Group will concentrate exclusively on the operation of the specialist centres and the further growth of the international network to approximately 100 locations by 2023/2024. HAEMATO AG will focus even more strongly on the area of pharmaceutical and medical product trading and the development of private labels in the self-payer sector.

M1 Kliniken AG expects consolidated sales of more than €150 million in fiscal year 2020 and €250-300 million in fiscal year 2021 after the implementation of the transaction.

Patrick Brenske, CEO of M1 Kliniken AG comments on the transaction: "In recent years we have already achieved clear market leadership in the beauty treatment sector in Germany and in the medium term we are aiming for a comparable market position internationally. Through the clear focus on our beauty-business activities and their sustainable growth, we will be in an even better position to offer the highest quality at reasonable prices in the long-term".

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers.


Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


10.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

amalphi AG

Original-Research: amalphi AG (von Sphene Capital GmbH): Buy

25. September 2020